Current trends in biologics delivery to restore intervertebral disc anabolism
- PMID: 25174310
- DOI: 10.1016/j.addr.2014.08.008
Current trends in biologics delivery to restore intervertebral disc anabolism
Abstract
Low back pain is generally attributed to intervertebral disc (IVD) degeneration. This is a multifactorial disease induced by genetic and environmental factors and that progresses with aging. Disc degeneration is characterized by a limited ability of IVD cells to produce functional matrix while producing abnormal amounts of matrix-degrading enzymes. The prolonged imbalance between anabolism and catabolism in degenerative discs alters their composition and hydration. In turn, this results in increased angiogenesis and the loss of the disc's ability to maintain its aneural condition. Inflammation in the IVD, in particular the presence of pro-inflammatory cytokines, was found to favor innervation and also sensitization of the nociceptive pathways, thereby exacerbating degenerative symptoms. In this review, we discuss anti-inflammatory approaches to encounter disc catabolism, potential treatments to lower discogenic pain and pro-anabolic approaches in the form of protein delivery, gene therapy and cell delivery, to trigger regeneration in the IVD.
Keywords: Annulus fibrosus; Biomaterials; Cell therapy; Gene therapy; Growth factors; Inflammation; Intervertebral disc; Nucleus pulposus.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Treatment of the degenerated intervertebral disc; closure, repair and regeneration of the annulus fibrosus.J Tissue Eng Regen Med. 2015 Oct;9(10):1120-32. doi: 10.1002/term.1866. Epub 2014 Feb 25. J Tissue Eng Regen Med. 2015. PMID: 24616324 Review.
-
Delivery systems for the treatment of degenerated intervertebral discs.Adv Drug Deliv Rev. 2015 Apr;84:172-87. doi: 10.1016/j.addr.2014.10.024. Epub 2014 Oct 25. Adv Drug Deliv Rev. 2015. PMID: 25451138 Review.
-
Stem Cell Therapies for Treatment of Discogenic Low Back Pain: a Comprehensive Review.Curr Pain Headache Rep. 2019 Jul 29;23(9):65. doi: 10.1007/s11916-019-0804-y. Curr Pain Headache Rep. 2019. PMID: 31359164 Review.
-
Advancing the cellular and molecular therapy for intervertebral disc disease.Adv Drug Deliv Rev. 2015 Apr;84:159-71. doi: 10.1016/j.addr.2014.06.009. Epub 2014 Jun 30. Adv Drug Deliv Rev. 2015. PMID: 24993611 Review.
-
Current Knowledge and Future Therapeutic Prospects in Symptomatic Intervertebral Disc Degeneration.Yonsei Med J. 2022 Mar;63(3):199-210. doi: 10.3349/ymj.2022.63.3.199. Yonsei Med J. 2022. PMID: 35184422 Free PMC article. Review.
Cited by
-
Emerging role of circular RNA in intervertebral disc degeneration: Knowns and unknowns (Review).Mol Med Rep. 2020 Oct;22(4):3057-3065. doi: 10.3892/mmr.2020.11437. Epub 2020 Aug 19. Mol Med Rep. 2020. PMID: 32945490 Free PMC article. Review.
-
What is the preclinical evidence on platelet rich plasma and intervertebral disc degeneration?Eur Spine J. 2015 Nov;24(11):2377-86. doi: 10.1007/s00586-015-4189-2. Epub 2015 Aug 14. Eur Spine J. 2015. PMID: 26272374 Review.
-
Intervertebral Disc Nucleus Repair: Hype or Hope?Int J Mol Sci. 2019 Jul 24;20(15):3622. doi: 10.3390/ijms20153622. Int J Mol Sci. 2019. PMID: 31344903 Free PMC article. Review.
-
Polydopamine Nanoparticles Targeting Ferroptosis Mitigate Intervertebral Disc Degeneration Via Reactive Oxygen Species Depletion, Iron Ions Chelation, and GPX4 Ubiquitination Suppression.Adv Sci (Weinh). 2023 May;10(13):e2207216. doi: 10.1002/advs.202207216. Epub 2023 Mar 23. Adv Sci (Weinh). 2023. PMID: 36951540 Free PMC article.
-
PLK1 Mitigates Intervertebral Disc Degeneration by Delaying Senescence of Nucleus Pulposus Cells.Front Cell Dev Biol. 2022 Mar 14;10:819262. doi: 10.3389/fcell.2022.819262. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35372354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical